When it comes to clinical trials, time is money. And a delay in a trial can mean a drop in a drug’s net value, lost ground to competitors, or an increased risk of failure — or it can signal more bad news to come.

But not all trial delays are red flags. How often is a pushed-back timeline a bad omen? How often is it a minor inconvenience? And how can you predict the difference? It’s not as easy as it sounds: It can be hard to get full information about trial delays, and details are often even sparser if the sponsor is a large pharma company or a private biotech.

In this special STAT Report, the first of three on clinical trials, biopharma consultant Frank David, M.D., Ph.D., author of two highly popular drug industry handbooks — “The Pharmagellan Guide to Analyzing Biotech Clinical Trials” and “The Pharmagellan Guide to Biotech Forecasting and Valuation” — provides the answers that people who track the progress of clinical trials need most. 

In this 28 page report, you will find:

• Information about the various causes of trial delays, their potential impacts, and how to tell if you should be worried or not.

• Insights from real-life examples of companies whose trials were pushed back.

• Proprietary analyses of the frequency, length, and impact of holdups in a clinical trial’s timeline.

Interested in more reports on clinical trials?

Gain special access to Frank David’s clinical trial series for a fraction of the cost. This bundle deal gives you a discount on all three reports focused on clinical trials.

Add the below reports to your cart and use the discount code BUNDLE at checkout to save $150.

• Clinical trial delays: What they mean and why you should care
• Failed trial, successful drug: How a negative readout can lead to FDA approval
• Clinical trial subgroup analysis: How to evaluate post hoc tests for significance in clinical trials